Nanomedical engineering: Shaping future nanomedicines

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 7, Issue 2, 2015, Pages 169-188

  Luo, Dandan ^a   Carter, Kevin A ^a,b   Lovell, Jonathan F ^a,b  

^a The State University of New York   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; MEDICAL NANOTECHNOLOGY;

CLINICAL TRANSLATION; COMPLEX PROPERTIES; DESIGN CRITERIA; RESEARCH ADVANCES; TRIGGERED DRUG RELEASE;

DRUG DELIVERY;

COPOLYMER; DENDRIMER; GOLD NANOPARTICLE; LIPOSOME; MACROGOL; MAGNETIC NANOPARTICLE; NANOCARRIER; DRUG CARRIER; NANOPARTICLE;

BIOCOMPATIBILITY; BIOMEDICAL ENGINEERING; CHEMOTHERAPY; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG TARGETING; DRUG TOXICITY; HEATING; HUMAN; LIGHT; MAGNETISM; MEDICAL RESEARCH; NANOENGINEERING; NANOMEDICAL ENGINEERING; NANOMEDICINE; PRIORITY JOURNAL; REVIEW; SURFACE CHARGE; ULTRASOUND; CHEMISTRY; NANOTECHNOLOGY; PROCEDURES; TRENDS;

DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY;

EID: 84921510378     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.1315     Document Type: Review

References (160)

1. Kim BYS, Rutka JT, Chan WCW. Nanomedicine. N Engl J Med 2010, 363:2434-2443.
2. Agasti SS, Rana S, Park M-H, Kim CK, You C-C, Rotello VM. Nanoparticles for detection and diagnosis. Adv Drug Deliv Rev 2010, 62:316-328.
3. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
4. Mulder WJM, Jaffer FA, Fayad ZA, Nahrendorf M. Imaging and nanomedicine in inflammatory atherosclerosis. Sci Transl Med 2014, 6:239sr1.
5. Pison U, Welte T, Giersig M, Groneberg DA. Nanomedicine for respiratory diseases. Eur J Pharmacol 2006, 533:341-350.
6. Wagner V, Dullaart A, Bock A-K, Zweck A. The emerging nanomedicine landscape. Nat Biotechnol 2006, 24:1211-1217.
7. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Controlled Release 2000, 65:271-284.
8. Dong X, Mattingly CA, Tseng MT, Cho MJ, Liu Y, Adams VR, Mumper RJ. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res 2009, 69:3918-3926.
9. Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res 2004, 21:201-230.
10. Hamburg MA. FDA's approach to regulation of products of nanotechnology. Science 2012, 336:299-300.
11. Venditto VJ, Szoka FC Jr. Cancer nanomedicines: so many papers and so few drugs!. Adv Drug Deliv Rev 2013, 65:80-88.
12. Albanese A, Tang PS, Chan WCW. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng 2012, 14:1-16.
13. Choi HS, Ashitate Y, Lee JH, Kim SH, Matsui A, Insin N, Bawendi MG, Semmler-Behnke M, Frangioni JV, Tsuda A. Rapid translocation of nanoparticles from the lung airspaces to the body. Nat Biotechnol 2010, 28:1300-1303.
14. Soo Choi H, Liu W, Misra P, Tanaka E, Zimmer JP, Itty Ipe B, Bawendi MG, Frangioni JV. Renal clearance of quantum dots. Nat Biotechnol 2007, 25:1165-1170.
15. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J 2005, 19:311-330.
16. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010, 7:653-664.
17. Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WCW. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett 2009, 9:1909-1915.
18. Geng Y, Dalhaimer P, Cai S, Tsai R, Tewari M, Minko T, Discher DE. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol 2007, 2:249-255.
19. Liu Z, Cai W, He L, Nakayama N, Chen K, Sun X, Chen X, Dai H. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol 2007, 2:47-52.
20. Park J-H, von Maltzahn G, Zhang L, Schwartz MP, Ruoslahti E, Bhatia SN, Sailor MJ. Magnetic iron oxide nanoworms for tumor targeting and imaging. Adv Mater 2008, 20:1630-1635.
21. Wang J, Byrne JD, Napier ME, DeSimone JM. More effective nanomedicines through particle design. Small 2011, 7:1919-1931.
22. Steinmetz NF. Viral nanoparticles as platforms for next-generation therapeutics and imaging devices. Nanomed Nanotechnol Biol Med 2010, 6:634-641.
23. Pinheiro AV, Han D, Shih WM, Yan H. Challenges and opportunities for structural DNA nanotechnology. Nat Nanotechnol 2011, 6:763-772.
24. Perrault SD, Shih WM. Virus-inspired membrane encapsulation of DNA nanostructures to achieve in vivo stability. ACS Nano 2014, 8:5132-5140.
25. Turner MR, Clough G, Michel CC. The effects of cationised ferritin and native ferritin upon the filtration coefficient of single frog capillaries. Evidence that proteins in the endothelial cell coat influence permeability. Microvasc Res 1983, 25:205-222.
26. Dellian M, Yuan F, Trubetskoy VS, Torchilin VP, Jain RK. Vascular permeability in a human tumour xenograft: molecular charge dependence. Br J Cancer 2000, 82:1513-1518.
27. Lv H, Zhang S, Wang B, Cui S, Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J Controlled Release 2006, 114:100-109.
28. He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 2010, 31:3657-3666.
29. Liu X, Li H, Chen Y, Jin Q, Ren K, Ji J. Mixed-charge nanoparticles for long circulation, low reticuloendothelial system clearance, and high tumor accumulation. Adv Healthc Mater 2014, 3:1439-1447.
30. Xiao W, Lin J, Li M, Ma Y, Chen Y, Zhang C, Li D, Gu H. Prolonged in vivo circulation time by zwitterionic modification of magnetite nanoparticles for blood pool contrast agents. Contrast Media Mol Imaging 2012, 7:320-327.
31. Walkey CD, Chan WCW. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chem Soc Rev 2012, 41:2780.
32. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003, 2:214-221.
33. Owens DE III, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006, 307:93-102.
34. Schellekens H, Hennink WE, Brinks V. The immunogenicity of polyethylene glycol: facts and fiction. Pharm Res 2013, 30:1729-1734.
35. Hu C-MJ, Zhang L, Aryal S, Cheung C, Fang RH, Zhang L. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci U S A 2011, 108:10980-10985.
36. Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci 2002, 6:319-327.
37. Moghimi SM, Hunter AC, Andresen TL. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu Rev Pharmacol Toxicol 2012, 52:481-503.
38. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A 1998, 95:4607-4612.
39. Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol Semin Orig Investig 2008, 26:57-64.
40. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 2008, 60:1615-1626.
41. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002, 2:750-763.
42. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006, 66:6732-6740.
43. Pirollo KF, Chang EH. Does a targeting ligand influence nanoparticle tumor localization or uptake? Trends Biotechnol 2008, 26:552-558.
44. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, et al. Anti-HER2 immunoliposomes enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002, 8:1172-1181.
45. Niu G. Why integrin as a primary target for imaging and therapy. Theranostics 2011, 1:30-47.
46. Ruoslahti E. Rgd and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996, 12:697-715.
47. Mitra A, Mulholland J, Nan A, McNeill E, Ghandehari H, Line BR. Targeting tumor angiogenic vasculature using polymer-RGD conjugates. J Controlled Release 2005, 102:191-201.
48. Dubey PK, Mishra V, Jain S, Mahor S, Vyas SP. Liposomes modified with cyclic RGD peptide for tumor targeting. J Drug Target 2004, 12:257-264.
49. Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001, 37(suppl 4):9-15.
50. Qian ZM, Li H, Sun H, Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 2002, 54:561-587.
51. Davis ME, Zuckerman JE, Choi CHJ, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
52. Choi CHJ, Alabi CA, Webster P, Davis ME. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci U S A 2010, 107:1235-1240.
53. Low PS, Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol 2009, 13:256-262.
54. Yoo HS, Park TG. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J Controlled Release 2004, 96:273-283.
55. Wang X, Li J, Wang Y, Cho KJ, Kim G, Gjyrezi A, Koenig L, Giannakakou P, Shin HJ, Tighiouart M, et al. HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. ACS Nano 2009, 3:3165-3174.
56. Bangham AD, Horne RW. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J Mol Biol 1964, 8:660-668.
57. Nie S. Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine 2010, 5:523-528.
58. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 1990, 268:235-237.
59. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999, 51:691-744.
60. Constantinides PP, Chaubal MV, Shorr R. Advances in lipid nanodispersions for parenteral drug delivery and targeting. Adv Drug Deliv Rev 2008, 60:757-767.
61. Mulder WJM, Strijkers GJ, van Tilborg GAF, Griffioen AW, Nicolay K. Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed 2006, 19:142-164.
62. Ng KK, Lovell JF, Zheng G. Lipoprotein-inspired nanoparticles for cancer theranostics. Acc Chem Res 2011, 44:1105-1113.
63. ®-the first FDA-approved nano-drug: lessons learned. J Controlled Release 2012, 160:117-134.
64. Boswell GW, Buell D, Bekersky I. AmBisome (liposomal amphotericin B): a comparative review. J Clin Pharmacol 1998, 38:583-592.
65. Fanos V, Cataldi L. Amphotericin B-induced nephrotoxicity: a review. J Chemother 2000, 12:463-470.
66. ® (extended-release epidural morphine): a review of an old drug in a new vehicle. Tech Reg Anesth Pain Manage 2007, 11:9-18.
67. Huynh E, Zheng G. Porphysome nanotechnology: a paradigm shift in lipid-based supramolecular structures. Nano Today 2014, 9:212-222.
68. Zhang Y, Lovell JF. Porphyrins as theranostic agents from prehistoric to modern times. Theranostics 2012, 2:905-915.
69. Jin CS, Lovell JF, Chen J, Zheng G. Ablation of hypoxic tumors with dose-equivalent photothermal, but not photodynamic, therapy using a nanostructured porphyrin assembly. ACS Nano 2013, 7:2541-2550.
70. Jin CS, Cui L, Wang F, Chen J, Zheng G. Targeting-triggered porphysome nanostructure disruption for activatable photodynamic therapy. Adv Healthc Mater 2014, 3:1240-1249.
71. Lovell JF, Jin CS, Huynh E, Jin H, Kim C, Rubinstein JL, Chan WCW, Cao W, Wang LV, Zheng G. Porphysome nanovesicles generated by porphyrin bilayers for use as multimodal biophotonic contrast agents. Nat Mater 2011, 10:324-332.
72. MacDonald TD, Liu TW, Zheng G. An MRI-sensitive, non-photobleachable porphysome photothermal agent. Angew Chem Int Ed Engl 2014, 53:6956-6959.
73. Liu TW, MacDonald TD, Jin CS, Gold JM, Bristow RG, Wilson BC, Zheng G. Inherently multimodal nanoparticle-driven tracking and real-time delineation of orthotopic prostate tumors and micrometastases. ACS Nano 2013, 7:4221-4232.
74. Lee J-H, Shao S, Cheng KT, Lovell JF, Paik CH. 99mTc-labeled porphyrin-lipid nanovesicles. J Liposome Res 2014:1-6. doi:10.3109/08982104.2014.932379.
75. Carter KA, Shao S, Hoopes MI, Luo D, Ahsan B, Grigoryants VM, Song W, Huang H, Zhang G, Pandey RK, et al. Porphyrin-phospholipid liposomes permeabilized by near-infrared light. Nat Commun 2014, 5:3546. doi: 10.1038/ncomms4546.
76. Volder MFLD, Tawfick SH, Baughman RH, Hart AJ. Carbon nanotubes: present and future commercial applications. Science 2013, 339:535-539.
77. Fu CH, Sakamoto KM. PEG-asparaginase. Expert Opin Pharmacother 2007, 8:1977-1984.
78. ®) for the treatment of hepatitis C. Adv Drug Deliv Rev 2002, 54:571-586.
79. Wang Y-S, Youngster S, Grace M, Bausch J, Bordens R, Wyss DF. Structural and biological characterization of pegylated recombinant interferon α-2b and its therapeutic implications. Adv Drug Deliv Rev 2002, 54:547-570.
80. Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des 2004, 10:1235-1244.
81. Satchi R, Connors TA, Duncan R. PDEPT: polymer-directed enzyme prodrug therapy. Br J Cancer 2001, 85:1070-1076.
82. Satchi-Fainaro R, Hailu H, Davies JW, Summerford C, Duncan R. PDEPT: polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-β-lactamase and HPMA copolymer-C-Dox as a model combination. Bioconjug Chem 2003, 14:797-804.
83. Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, Thomson AH, Murray LS, Hilditch TE, Murray T, et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin Cancer Res 1999, 5:83-94.
84. Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan PJ, Poyner R, Doran J, Young AM, Burtles S, Kerr DJ. Hepatic drug targeting: phase i evaluation of polymer-bound doxorubicin. J Clin Oncol 2002, 20:1668-1676.
85. Meerum Terwogt JM, ten Bokkel Huinink WW, Schellens JH, Schot M, Mandjes IA, Zurlo MG, Rocchetti M, Rosing H, Koopman FJ, Beijnen JH. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anti-Cancer Drugs 2001, 12:315-323.
86. Singer JW. Paclitaxel poliglumex (XYOTAX™, CT-2103): a macromolecular taxane. J Controlled Release 2005, 109:120-126.
87. Bhatt R, de Vries P, Tulinsky J, Bellamy G, Baker B, Singer JW, Klein P. Synthesis and in vivo antitumor activity of poly(l-glutamic acid) conjugates of 20(S)-camptothecin. J Med Chem 2003, 46:190-193.
88. Danhauser-Riedl S, Hausmann E, Schick H-D, Bender R, Dietzfelbinger H, Rastetter J, Hanauske AR. Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Invest New Drugs 1993, 11:187-195.
89. Lee KS, Chung HC, Im SA, Park YH, Kim CS, Kim S-B, Rha SY, Lee MY, Ro J. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 2008, 108:241-250.
90. ®-PM) in patients with solid tumors. Ann Oncol 2010, 21:382-388.
91. Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 2008, 60:876-885.
92. Hrkach J, Hoff DV, Ali MM, Andrianova E, Auer J, Campbell T, De Witt D, Figa M, Figueiredo M, Horhota A, et al. Preclinical development and clinical translation of a PSMA-targeted Docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012, 4:128ra39.
93. Venne A, Li S, Mandeville R, Kabanov A, Alakhov V. Hypersensitizing effect of Pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res 1996, 56:3626-3629.
94. Batrakova EV, Li S, Elmquist WF, Miller DW, Alakhov VY, Kabanov AV. Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: selective energy depletion. Br J Cancer 2001, 85:1987-1997.
95. Zhang Y, Jeon M, Rich LJ, Hong H, Geng J, Zhang Y, Shi S, Barnhart TE, Alexandridis P, Huizinga JD, et al. Non-invasive multimodal functional imaging of the intestine with frozen micellar naphthalocyanines. Nat Nanotechnol 2014, 9:631-638.
96. Nanjwade BK, Bechra HM, Derkar GK, Manvi FV, Nanjwade VK. Dendrimers: emerging polymers for drug-delivery systems. Eur J Pharm Sci 2009, 38:185-196.
97. Lee CC, MacKay JA, Fréchet JMJ, Szoka FC. Designing dendrimers for biological applications. Nat Biotechnol 2005, 23:1517-1526.
98. Rupp R, Rosenthal SL, Stanberry LR. VivaGel™ (SPL7013 Gel): a candidate dendrimer-microbicide for the prevention of HIV and HSV infection. Int J Nanomedicine 2007, 2:561-566.
99. ®) in sexually active young women (MTN-004). AIDS Lond Engl 2011, 25:1057-1064.
100. Auffan M, Rose J, Bottero J-Y, Lowry GV, Jolivet J-P, Wiesner MR. Towards a definition of inorganic nanoparticles from an environmental, health and safety perspective. Nat Nanotechnol 2009, 4:634-641.
101. Giljohann DA, Seferos DS, Daniel WL, Massich MD, Patel PC, Mirkin CA. Gold nanoparticles for biology and medicine. Angew Chem Int Ed 2010, 49:3280-3294.
102. Wu G, Mikhailovsky A, Khant HA, Fu C, Chiu W, Zasadzinski JA. Remotely triggered liposome release by near-infrared light absorption via hollow gold nanoshells. J Am Chem Soc 2008, 130:8175-8177.
103. Huang X, El-Sayed IH, Qian W, El-Sayed MA. Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. J Am Chem Soc 2006, 128:2115-2120.
104. Murphy CJ, Gole AM, Stone JW, Sisco PN, Alkilany AM, Goldsmith EC, Baxter SC. Gold nanoparticles in biology: beyond toxicity to cellular imaging. Acc Chem Res 2008, 41:1721-1730.
105. Paciotti GF, Myer L, Weinreich D, Goia D, Pavel N, McLaughlin RE, Tamarkin L. Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv 2004, 11:169-183.
106. Libutti SK, Paciotti GF, Byrnes AA, Alexander HR, Gannon WE, Walker M, Seidel GD, Yuldasheva N, Tamarkin L. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res 2010, 16:6139-6149.
107. Ito A, Shinkai M, Honda H, Kobayashi T. Medical application of functionalized magnetic nanoparticles. J Biosci Bioeng 2005, 100:1-11.
108. Cai W, Shin D-W, Chen K, Gheysens O, Cao Q, Wang SX, Gambhir SS, Chen X. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett 2006, 6:669-676.
109. Byers RJ, Hitchman ER. Quantum dots brighten biological imaging. Prog Histochem Cytochem 2011, 45:201-237.
110. Resch-Genger U, Grabolle M, Cavaliere-Jaricot S, Nitschke R, Nann T. Quantum dots versus organic dyes as fluorescent labels. Nat Methods 2008, 5:763-775.
111. Wu X, Liu H, Liu J, Haley KN, Treadway JA, Larson JP, Ge N, Frank Peale F, Bruchez MP. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat Biotechnol 2003, 21:41-46.
112. Park KH, Chhowalla M, Iqbal Z, Sesti F. Single-walled carbon nanotubes are a new class of ion channel blockers. J Biol Chem 2003, 278:50212-50216.
113. Klumpp C, Kostarelos K, Prato M, Bianco A. Functionalized carbon nanotubes as emerging nanovectors for the delivery of therapeutics. Biochim Biophys Acta 2006, 1758:404-412.
114. Wang J. Carbon-nanotube based electrochemical biosensors: a review. Electroanalysis 2005, 17:7-14.
115. Gao W, Chan JM, Farokhzad OC. pH-responsive nanoparticles for drug delivery. Mol Pharm 2010, 7:1913-1920.
116. Delie F, Blanco-Príeto MJ. Polymeric particulates to improve oral bioavailability of peptide drugs. Molecules 2005, 10:65-80.
117. Damgé C, Maincent P, Ubrich N. Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J Controlled Release 2007, 117:163-170.
118. Chen M-C, Sonaje K, Chen K-J, Sung H-W. A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials 2011, 32:9826-9838.
119. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell 2008, 134:703-707.
120. Kratz F, Müller IA, Ryppa C, Warnecke A. Prodrug strategies in anticancer chemotherapy. ChemMedChem 2008, 3:20-53.
121. Lee ES, Bae YH. Recent progress in tumor pH targeting nanotechnology. J Controlled Release 2008, 132:164-170.
122. Meng F, Zhong Y, Cheng R, Deng C, Zhong Z. pH-sensitive polymeric nanoparticles for tumor-targeting doxorubicin delivery: concept and recent advances. Nanomedicine 2014, 9:487-499.
123. Chu C-J, Szoka FC. pH-sensitive liposomes. J Liposome Res 1994, 4:361-395.
124. Sethuraman VA, Bae YH. TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. J Controlled Release 2007, 118:216-224.
125. Lee ES, Gao Z, Kim D, Park K, Kwon IC, Bae YH. Super pH-sensitive multifunctional polymeric micelle for tumor pHe specific TAT exposure and multidrug resistance. J Controlled Release 2008, 129:228-236.
126. Lovell JF, Zheng G. Activatable smart probes for molecular optical imaging and therapy. J Innov Opt Health Sci 2008, 1:45-61.
127. Lovell JF, Liu TWB, Chen J, Zheng G. Activatable photosensitizers for imaging and therapy. Chem Rev 2010, 110:2839-2857.
128. De la Rica R, Aili D, Stevens MM. Enzyme-responsive nanoparticles for drug release and diagnostics. Adv Drug Deliv Rev 2012, 64:967-978.
129. Delcea M, Möhwald H, Skirtach AG. Stimuli-responsive LbL capsules and nanoshells for drug delivery. Adv Drug Deliv Rev 2011, 63:730-747.
130. Andresen TL, Jensen SS, Kaasgaard T, Jorgensen K. Triggered activation and release of liposomal prodrugs and drugs in cancer tissue by secretory phospholipase A2. Curr Drug Deliv 2005, 2:353-362.
131. Lovell JF, Jin CS, Huynh E, MacDonald TD, Cao W, Zheng G. Enzymatic regioselection for the synthesis and biodegradation of porphysome nanovesicles. Angew Chem 2012, 124:2479-2483.
132. Zhou H, Yan H, Senpan A, Wickline SA, Pan D, Lanza GM, Pham CTN. Suppression of inflammation in a mouse model of rheumatoid arthritis using targeted lipase-labile fumagillin prodrug nanoparticles. Biomaterials 2012, 33:8632-8640.
133. 3-targeted theranostic nanoparticles. Theranostics 2014, 4:565-578.
134. Wong C, Stylianopoulos T, Cui J, Martin J, Chauhan VP, Jiang W, Popović Z, Jain RK, Bawendi MG, Fukumurab D. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci U S A 2011, 108:2426-2431.
135. Yavlovich A, Singh A, Tarasov S, Capala J, Blumenthal R, Puri A. Design of liposomes containing photopolymerizable phospholipids for triggered release of contents. J Therm Anal Calorim 2009, 98:97-104.
136. Bae YH, Okano T, Hsu R, Kim SW. Thermo-sensitive polymers as on-off switches for drug release. Makromol Chem Rapid Commun 1987, 8:481-485.
137. Yatvin MB, Weinstein JN, Dennis WH, Blumenthal R. Design of liposomes for enhanced local release of drugs by hyperthermia. Science 1978, 202:1290-1293.
138. Fomina N, Sankaranarayanan J, Almutairi A. Photochemical mechanisms of light-triggered release from nanocarriers. Adv Drug Deliv Rev 2012, 64:1005-1020.
139. Brazel CS. Magnetothermally-responsive nanomaterials: combining magnetic nanostructures and thermally-sensitive polymers for triggered drug release. Pharm Res 2009, 26:644-656.
140. Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res 2000, 60:1197-1201.
141. Kong G, Anyarambhatla G, Petros WP, Braun RD, Colvin OM, Needham D, Dewhirst MW. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res 2000, 60:6950-6957.
142. Miller AD. Lipid-based nanoparticles in cancer diagnosis and therapy. J Drug Deliv 2013, 2013:e165981.
143. Poon RT, Borys N. Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer. Expert Opin Pharmacother 2009, 10:333-343.
144. Hong CW, Libutti SK, Wood BJ. Liposomal doxorubicin plus radiofrequency ablation for complete necrosis of a hepatocellular carcinoma. Curr Oncol 2013, 20:e274-e277.
145. Hu S-H, Chen S-Y, Liu D-M, Hsiao C-S. Core/single-crystal-shell nanospheres for controlled drug release via a magnetically triggered rupturing mechanism. Adv Mater 2008, 20:2690-2695.
146. Babincová M, Cicmanec P, Altanerová V, Altaner C, Babinec P. AC-magnetic field controlled drug release from magnetoliposomes: design of a method for site-specific chemotherapy. Bioelectrochemistry 2002, 55:17-19.
147. Amstad E, Kohlbrecher J, Müller E, Schweizer T, Textor M, Reimhult E. Triggered release from liposomes through magnetic actuation of iron oxide nanoparticle containing membranes. Nano Lett 2011, 11:1664-1670.
148. Derfus AM, von Maltzahn G, Harris TJ, Duza T, Vecchio KS, Ruoslahti E, Bhatia SN. Remotely triggered release from magnetic nanoparticles. Adv Mater 2007, 19:3932-3936.
149. Bringas E, Köysüren Ö, Quach DV, Mahmoudi M, Aznar E, Roehling JD, Marcos MD, Martínez-Máñez R, Stroeve P. Triggered release in lipid bilayer-capped mesoporous silica nanoparticles containing SPION using an alternating magnetic field. Chem Commun 2012, 48:5647-5649.
150. Kobayashi T. Cancer hyperthermia using magnetic nanoparticles. Biotechnol J 2011, 6:1342-1347.
151. Kopechek JA, Abruzzo TM, Wang B, Chrzanowski SM, Smith DAB, Kee PH, Huang S, Collier JH, McPherson DD, Holland CK. Ultrasound-mediated release of hydrophilic and lipophilic agents from echogenic liposomes. J Ultrasound Med 2008, 27:1597-1606.
152. De Geest BG, Skirtach AG, Mamedov AA, Antipov AA, Kotov NA, De Smedt SC, Sukhorukov GB. Ultrasound-triggered release from multilayered capsules. Small 2007, 3:804-808.
153. Kim H-J, Matsuda H, Zhou H, Honma I. Ultrasound-triggered smart drug release from a poly(dimethylsiloxane)-mesoporous silica composite. Adv Mater 2006, 18:3083-3088.
154. Rapoport NY, Christensen DA, Fain HD, Barrows L, Gao Z. Ultrasound-triggered drug targeting of tumors in vitro and in vivo. Ultrasonics 2004, 42:943-950.
155. Dromi S, Frenkel V, Luk A, Traughber B, Angstadt M, Bur M, Poff J, Xie J, Libutti SK, Li KC, et al. Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res 2007, 13:2722-2727.
156. Schroeder A, Honen R, Turjeman K, Gabizon A, Kost J, Barenholz Y. Ultrasound triggered release of cisplatin from liposomes in murine tumors. J Controlled Release 2009, 137:63-68.
157. Tong R, Kohane DS. Shedding light on nanomedicine. WIREs Nanomed Nanobiotechnol 2012, 4:638-662.
158. Koçer A, Walko M, Meijberg W, Feringa BL. A light-actuated nanovalve derived from a channel protein. Science 2005, 309:755-758.
159. Leung SJ, Romanowski M. Light-activated content release from liposomes. Theranostics 2012, 2:1020-1036.
160. Yavlovich A, Smith B, Gupta K, Blumenthal R, Puri A. Light-sensitive lipid-based nanoparticles for drug delivery: design principles and future considerations for biological applications. Mol Membr Biol 2010, 27:364-381.